Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.52 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP5 | P51878 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545692 | 0.86 | ALDH1A1 (0.58) | CYP3A4CYP2D6HRH3KDM4EALDH1A1 | |
| SCHEMBL4935986 | 0.86 | ALDH1A1 (0.54) | CYP3A4CYP2D6KDM4EALDH1A1GAA | |
| SCHEMBL29967920 | 0.86 | ALDH1A1 (0.58) | CYP3A4CYP2D6HRH3KDM4EALDH1A1 | |
| SCHEMBL3185946 | 0.85 | MAPT (0.46) | HIF1AEPAS1NCF1HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30349712 | 0.84 | ALDH1A1 (0.56) | CYP3A4CYP2D6HRH3KDM4EALDH1A1 | |
| SCHEMBL545978 | 0.84 | ALDH1A1 (0.60) | CYP3A4CYP2D6HRH3KDM4EALDH1A1 | |
| SCHEMBL447632 | 0.83 | SIGMAR1 (0.50) | HIF1AEPAS1KDM4EALDH1A1LMNA | |
| SCHEMBL545449 | 0.82 | LMNA (0.53) | CYP3A4CYP2D6NCF1KDM4EALDH1A1 | |
| SCHEMBL16907553 | 0.82 | CYP2D6 (0.59) | CYP3A4CYP2D6HRH3KDM4EALDH1A1 | |
| SCHEMBL21950469 | 0.82 | HIF1A (0.52) | HIF1AEPAS1CYP3A4CYP2D6NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313972-B1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-01-29 | — | — | EP | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| EP-4313972-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117062812-A | Indoline derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116829548-A | Pyrazole derivatives as C-ABL inhibitors | 博善人工智能生物科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022200577-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-29 | — | — | WO | disclosed |
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-08-09 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | HIF1A 1526/4885EPAS1 1577/4885CYP3A4 1046/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | HIF1A 172/4885EPAS1 446/4885CYP3A4 207/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HIF1A 130/4885EPAS1 320/4885CYP3A4 67/4885 |
| US-11407745-B2 | Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same | ABL1, DDR1, ABL2 | HIF1A 2802/4885EPAS1 1736/4885CYP3A4 2274/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HIF1A 214/4885EPAS1 337/4885CYP3A4 385/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | HIF1A 130/4885EPAS1 320/4885CYP3A4 67/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HIF1A 214/4885EPAS1 337/4885CYP3A4 385/4885 |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | HIF1A 3247/4885EPAS1 497/4885CYP3A4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.